FER-TH-007: Phase II Study of Bevacizumab and Erlotinib in Elderly Patients with Advanced Non-Small Cell Lung Cancer.

Trial Profile

FER-TH-007: Phase II Study of Bevacizumab and Erlotinib in Elderly Patients with Advanced Non-Small Cell Lung Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms NSCLC
  • Most Recent Events

    • 04 Feb 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017 as reported by ClinicalTrials.gov.
    • 04 Sep 2015 Planned End Date changed from 1 Apr 2015 to 1 Apr 2016 as per ClinicalTrials.gov record.
    • 04 Sep 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Apr 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top